| ICI | Immune Checkpoint Inhibitor |
| CTLA-4 | Cytotoxic T-Lymphocyte-associated Antigen-4 |
| PD-1 | Programmed cell death protein-1 |
| IRAEs | Immune-Related Adverse Events |
| GCP | Good Clinical Practice |
| AJCC | American Joint Committee on Cancer |
| NLR | Neutrophils-to-Lymphocytes Ratio |
| FDG-PET/CT18F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomography | |
| RECIST 1.1. | Response Evaluation Criteria in Solid Tumors version 1.1. |
| PD | Progressive Disease |
| CB | Clinical Benefit |
| CR | Complete Response |
| PR | Partial Response |
| SD | Stable Disease |
| OS | Overall Survival |
| PFS | Progression-free survival PFS |
| MTV | Metabolic Tumor Volume |
| TLG | Total Lesion Glycolysis |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.